Trial Profile
Phase 1, Open-label, 3-Parts Study With Crossover Design in Each Part to Investigate the Bioequivalence of the Tablet Formulation of TF3 Compared to TF2 (Part A), and to Investigate the Influence of Food on the PK of Each TF2 (Part B) and TF3 (Part C) of Tepotinib in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Oct 2023
Price :
$35
*
At a glance
- Drugs Tepotinib (Primary)
- Indications Liver cancer; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Merck KGaA
- 06 Oct 2023 Number of treatment arms have been decreased from 8 to 6 by the removal of the following two optional arms- Part A, Stage 2.
- 12 Mar 2019 Status changed from not yet recruiting to completed.
- 23 Aug 2018 New trial record